VEGFA and neoplasm: The EGFR kinase inhibitor erlotinib was evaluated in a phase II trial of unselected patients with advanced BC having had previously received chemotherapy.21 In addition, erlotinib was evaluated in combination with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab.22 Both of these studies determined that erlotinib did not provide clinical benefit to BC patients and erlotinib responsiveness was not predicted by EGFR expression levels in the primary tumor.